Azithromycin is at least as effective as doxycycline in the treatment of moderate acne vulgaris; however, in patients older than 18 years doxycycline is better.

Objective: To examine the possible associations between Demodex folliculorum and a number of skin diseases. Methods: Standardized skin surface biopsy samples were obtained from the cheeks of 144 patients with histopathologically proven basal cell carcinoma (BCC, n=27), squamous cell carcinoma (SCC, n=28), melanoma (n=23), discoid lupus erythematosus (DLE, n=32), and rosacea (n=34). Thirty-four sex-and age-matched healthy volunteers served as controls. Mite density (per cm 2 ) and infestation (density≥5) were compared between the controls and patients. Results: Mite infestation rates (%) did not differ significantly between the controls (20.6) and patients with BCC (22.2, p=0.88), SCC (17.9, p=0.79), melanoma (4.3, p=0.08), and DLE (21.9, p=0.90). Compared with the controls, the mite infestation rate was significantly higher in patients with rosacea (47.1, p=0.02, odds ratio: 3.43, 95% confidence interval: 1.18-9.99). The mean mite density did not differ significantly between the controls (4.11±2.17) and patients with BCC (5.34±2.35, p=0.75), SCC (3.57±2.01, p=0.38), and DLE (3.56±1.34, p=0.83), whereas it was significantly higher in patients with rosacea (8.78±3.58, p=0.02) and lower in patients with melanoma (1.89±0.69, p=0.02). Conclusions: D. folliculorum may be associated with rosacea and melanoma but not with BCC, SCC, or DLE. Metot: Standardize yüzeyel deri biyopsisi örnekleri; bazal hücreli karsinom (BCC, n=27), skuamöz hücreli karsinom (SCC, n=28), melanom (n=23), diskoid lupus eritematozus (DLE, n=32), ve rozasea (n=34) tanıları histopatolojik olarak kanıtlanmış 144 hastanın yanaklarından alındı. Cinsiyet ve yaşı eşleştirilmiş 34 sağlıklı gönüllü kontrol grubunu oluşturdu. Akar dansitesi (cm 2 başına) ve enfestasyon (dansite≥5) hasta ve kontrol grubu arasında karşılaştırıldı. Bulgular: Akar enfestasyon hızları (%) kontrol grubu (20,6) ile BCC (22,2, p=0,88), SCC (17,9, p=0,79), melanom (4,3, p=0,08), ve DLE (21,9, p=0,90) hastaları arasında anlamlı bir farklılık göstermedi. Kontrol grubuna kıyasla, akar enfestasyon hızı, rozasea olanlarda anlamlı olarak yüksekti (47,1, p=0,02; odds oranı: 3,43, %95 güven aralığı: 1,18-9,99). Ortalama akar dansitesi kontrol grubu (4,11±2,17) ile BCC (5,34±2,35, p=0,75), SCC (3,57±2,01, p=0,38), ve DLE (3,56±1,34, p=0,83) hasta grupları arasında anlamlı bir fark göstermezken, kontrol grubuna kıyasla

Background:Acne vulgaris is an inflammatory disease of the pilosebaceous units. Various systemic and topical options are available for its treatment.Aims:This study aimed to evaluate the efficacy of 2% metronidazole gel in acne vulgaris.Materials and Methods:Double-blind, randomized, placebo-controlled, split-face clinical trial. Seventy young adults with moderate acne vulgaris received 2% metronidazole gel on the right side of their face and placebo on the left side of their face twice daily for 8 weeks. The number of inflamed and noninflamed facial lesions and side effects of treatment were documented on weeks 1, 2, 4, and 8. The patients’ overall satisfaction was recorded at the end of the study. For statistical analysis we used the repeated-measures analysis, the chi-square test, Fisher's exact test, and the independent-samples t-test as appropriate.Results:Counts of inflamed and noninflamed facial lesions were comparable between the two sides at baseline. The number of the lesions was significantly lower on the metronidazole-treated side at all follow-up visits. Erythema and oily face decreased by 85.7% and 87.1%, respectively, on the metronidazole-treated side. Mild burning sensation and dryness on the metronidazole-treated side was reported by 3.4% and 22.9% of the patients, respectively. Eighty-eight percent of the patients were satisfied with the results of treatment on the metronidazole-treated side.Conclusions:Metronidazole gel (2%) is an effective, safe, and well-tolerated topical medication for moderate acne vulgaris.

No abstract